[{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "619 949 3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 593, "companyOfficers": [{"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 68, "title": "President & Chairman", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 10500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 121352, "exercisedValue": 0, "unexercisedValue": 15073756}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 274617, "exercisedValue": 0, "unexercisedValue": 41527968}, {"maxAge": 1, "name": "Ms. Seline E. Miller CPA", "age": 54, "title": "Senior Vice President of Finance", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.78, "open": 11.78, "dayLow": 11.78, "dayHigh": 12.16, "regularMarketPreviousClose": 11.78, "regularMarketOpen": 11.78, "regularMarketDayLow": 11.78, "regularMarketDayHigh": 12.16, "forwardPE": 26.043476, "volume": 29399, "regularMarketVolume": 29399, "averageVolume": 106469, "averageVolume10days": 48410, "averageDailyVolume10Day": 48410, "bid": 8.6, "ask": 15.3, "bidSize": 200, "askSize": 200, "marketCap": 1028151168, "fiftyTwoWeekLow": 8.26, "fiftyTwoWeekHigh": 26.37, "priceToSalesTrailing12Months": 9.788839, "fiftyDayAverage": 11.1666, "twoHundredDayAverage": 12.5395, "currency": "USD", "enterpriseValue": 1040148800, "profitMargins": -0.84566003, "floatShares": 16098542, "sharesOutstanding": 85822304, "sharesShort": 1248253, "sharesShortPriorMonth": 952311, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0145000005, "heldPercentInsiders": 0.74626, "heldPercentInstitutions": 0.01958, "shortRatio": 12.46, "shortPercentOfFloat": 0.1857, "impliedSharesOutstanding": 85822304, "bookValue": 0.737, "priceToBook": 16.255087, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.717, "netIncomeToCommon": -88822000, "trailingEps": -1.04, "forwardEps": 0.46, "lastSplitFactor": "1:15", "lastSplitDate": 1698710400, "enterpriseToRevenue": 9.903, "enterpriseToEbitda": 88.133, "52WeekChange": -0.22192866, "SandP52WeekChange": 0.22903383, "lastDividendValue": 3.6, "lastDividendDate": 1673568000, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GYRE", "underlyingSymbol": "GYRE", "shortName": "Gyre Therapeutics, Inc.", "longName": "Gyre Therapeutics, Inc.", "firstTradeDateEpochUtc": 1144848600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fcf12068-c88b-34d0-8632-7e45e01ea8d2", "messageBoardId": "finmb_100542295", "gmtOffSetMilliseconds": -18000000, "currentPrice": 11.98, "recommendationKey": "none", "totalCash": 25092000, "totalCashPerShare": 0.292, "ebitda": 11802000, "totalDebt": 1795000, "quickRatio": 3.111, "currentRatio": 3.724, "totalRevenue": 105033000, "debtToEquity": 1.823, "revenuePerShare": 1.285, "returnOnEquity": -0.85323995, "grossProfits": 101076000, "operatingCashflow": 2477000, "earningsGrowth": -0.738, "revenueGrowth": -0.205, "grossMargins": 0.96233004, "ebitdaMargins": 0.11236, "operatingMargins": 0.16608, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]